🚀 Gate Square Creator Certification Incentive Program Is Live!
Join Gate Square and share over $10,000 in monthly creator rewards!
Whether you’re an active Gate Square creator or an established voice on another platform, consistent quality content can earn you token rewards, exclusive Gate merch, and massive traffic exposure!
✅ Eligibility:
You can apply if you meet any of the following:
1️⃣ Verified creator on another platform
2️⃣ At least 1,000 followers on a single platform (no combined total)
3️⃣ Gate Square certified creator meeting follower and engagement criteria
Click to apply now 👉
Kangle Guardian announces the unblinding of the Phase III clinical trial of the trivalent HPV vaccine, and the interim analysis is as expected.
Jinshi data, August 14th, Kang Lewei announced that the independent data monitoring committee for the phase III protection efficacy clinical trial of the recombinant trivalent human papillomavirus (16/18/58 type) vaccine (Escherichia coli) independently developed by Kang Lewei has completed the mid-term analysis unblinding, main efficacy indicators and safety assessment, and the results meet expectations.